This Article Abstract Full Text Full Text (PDF) View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waseda, K. Search for Related Content PubMed Articles by Waseda, K.

Intravascular Ultrasound Results From the ENDEAVOR IV Trial

Randomized Comparison Between Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease

Katsuhisa Waseda, MD, PhD^_*, Akiyoshi Miyazawa, MD^_*, Junya Ako, MD, PhD^_*, Takao Hasegawa, MD^_*, Ichizo Tsujino, MD, PhD^_*, Ryota Sakurai, MD, PhD^_*, Paul G. Yock, MD^_*, Yasuhiro Honda, MD^_*, David E. Kandzari, MD, Martin B. Leon, MD, Peter J. Fitzgerald, MD, PhD^_*,_* for the ENDEAVOR IV Trial Investigators

^_* Center for Cardiovascular Technology, Division of Cardiovascular Medicine, Stanford University, Stanford, California
Scripps Green Hospital, La Jolla, California
Columbia University, New York, New York

View larger version (16K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Statistical Distribution of Percentage of Neointimal Obstruction for ZES and PES The distribution of percentage of neointimal obstruction of zotarolimus-eluting stent (ZES) was shifted to the right and average percentage of neointimal obstruction was significantly higher when compared with obstruction of paclitaxel-eluting stent (PES) (p < 0.01).